--- title: "The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears" type: "News" locale: "en" url: "https://longbridge.com/en/news/274007573.md" description: "Eliquis (apixaban) sales are expected to decline by 15.2% this year as its European market exclusivity expires in May 2026. The drug, developed by Bristol Myers Squibb and Pfizer, has generated approximately $82.6 billion in revenue since its launch in 2011. The impending patent expiry signals a significant shift in the anticoagulant market, as Eliquis has been a leading treatment for various cardiovascular conditions due to its safety profile and ease of use compared to traditional anticoagulants." datetime: "2026-01-28T14:49:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274007573.md) - [en](https://longbridge.com/en/news/274007573.md) - [zh-HK](https://longbridge.com/zh-HK/news/274007573.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274007573.md) | [繁體中文](https://longbridge.com/zh-HK/news/274007573.md) # The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears This year, sales of Bristol Myers Squibb’s (BMS) and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity on 19 May 2026. The BMS-Pfizer alliance has dominated the anticoagulant drug market, earning approximately $82.6bn in revenue since 2011, according to GlobalData’s Sales and Forecast Database. However, with the expiry date fast approaching, the loss of Eliquis’ exclusivity will inevitably mark the beginning of a major patent cliff. Eliquis first entered the European market in May 2011, following MHRA approvals for various thromboembolic diseases, revolutionising thromboprophylaxis. The second-generation direct oral anticoagulant (DOAC) Eliquis prevents clot formation through the direct and reversible inhibition of free and clot-bound factor Xa, a key enzyme in the clotting cascade. Unlike traditional anticoagulants, DOACs have significantly higher safety profiles, with the reduced need for monitoring, setting them apart from traditional anticoagulants such as warfarin. Such factors have led to its takeover as a first-line treatment or prophylaxis of various cardiovascular diseases, including pulmonary embolism and non-valvular atrial fibrillation. ### Related Stocks - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [Pfizer Inc. (PFE.US)](https://longbridge.com/en/quote/PFE.US.md) - [Bristol-Myers Squibb Company (BMY.US)](https://longbridge.com/en/quote/BMY.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [ProShares Ultra Health Care (RXL.US)](https://longbridge.com/en/quote/RXL.US.md) - [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Direxion Daily Phrmctcl&MdclBl3XShrsETF (PILL.US)](https://longbridge.com/en/quote/PILL.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) ## Related News & Research - [Faro Announces Collaboration with Bristol Myers Squibb to Scale Autonomous AI in Clinical Development](https://longbridge.com/en/news/281192593.md) - [Bristol Myers Squibb Evolves and Expands Standing in the Gaap To Advance More Equitable Care in Multiple Myeloma As Program Marks Ten Years](https://longbridge.com/en/news/281359503.md) - [Bristol Myers Squibb adding 3 medications on TrumpRx](https://longbridge.com/en/news/281075788.md) - [Bristol Myers Squibb EVP, Chief Financial Officer Sold Shares Worth Over $1.8M](https://longbridge.com/en/news/281573001.md) - [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/en/news/281522861.md)